KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

GoodRx Holdings (GDRX) EBITDA (2019 - 2026)

GoodRx Holdings' EBITDA history spans 7 years, with the latest figure at $22.7 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 24.77% to $22.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $87.5 million, a 32.87% increase, with the full-year FY2025 number at $91.7 million, up 30.34% from a year prior.
  • EBITDA hit $22.7 million in Q4 2025 for GoodRx Holdings, up from $14.6 million in the prior quarter.
  • Over the last five years, EBITDA for GDRX hit a ceiling of $26.8 million in Q2 2025 and a floor of -$38.3 million in Q3 2023.
  • Historically, EBITDA has averaged $7.1 million across 5 years, with a median of $11.5 million in 2021.
  • The widest YoY moves for EBITDA: up 552.38% in 2023, down 1152.85% in 2023.
  • Tracing GDRX's EBITDA over 5 years: stood at $11.8 million in 2021, then plummeted by 85.22% to $1.7 million in 2022, then tumbled by 1152.85% to -$18.3 million in 2023, then skyrocketed by 199.41% to $18.2 million in 2024, then rose by 24.77% to $22.7 million in 2025.
  • Business Quant data shows EBITDA for GDRX at $22.7 million in Q4 2025, $14.6 million in Q3 2025, and $26.8 million in Q2 2025.